{
    "clinical_study": {
        "@rank": "23534", 
        "arm_group": [
            {
                "arm_group_label": "Part 1: LEO 43204", 
                "arm_group_type": "Other", 
                "description": "Open-label, dose escalation, 2 days treatment"
            }, 
            {
                "arm_group_label": "Part 2: LEO 43204 x dose", 
                "arm_group_type": "Active Comparator", 
                "description": "X dose for 2 days treatment"
            }, 
            {
                "arm_group_label": "Part 2: LEO 43204 Y dose", 
                "arm_group_type": "Active Comparator", 
                "description": "Y dose for 2 days treatment"
            }, 
            {
                "arm_group_label": "Part 2: Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for 2 days treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "To identify the Maximum Tolerated Dose levels of LEO 43204 after once daily treatment for\n      two consecutive days and to evaluate efficacy of LEO 43204 in two doses after once daily\n      treatment for two consecutive days compared to vehicle"
        }, 
        "brief_title": "Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Actinic Keratosis", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Part 1: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the\n             full balding scalp.\n\n          -  Part 2: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the\n             full balding scalp\n\n        Exclusion Criteria:\n\n          -  Location of the treatment area\n\n               -  within 5 cm of an incompletely healed wound\n\n               -  within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma\n                  (SCC)\n\n          -  Prior treatment with ingenol mebutate gel on the treatment area\n\n          -  Lesions in the treatment areas that have\n\n               -  atypical clinical appearance (e.g., hypertrophic, hyperkeratotic or cutaneous\n                  horns) and/or\n\n               -  recalcitrant disease (e.g., did not respond to cryotherapy on two previous\n                  occasions)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "205", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100813", 
            "org_study_id": "LP0084-1014", 
            "secondary_id": "2014-000037-23"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part 1: LEO 43204", 
                    "Part 2: LEO 43204 x dose", 
                    "Part 2: LEO 43204 Y dose"
                ], 
                "intervention_name": "LEO 43204", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part 2: Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "contact": {
                "last_name": "Jonathan Weiss, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Snellville", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30078"
                }, 
                "name": "Gwinnett Clinical Research Center, Inc."
            }, 
            "investigator": {
                "last_name": "Jonathan Weiss, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis", 
        "overall_contact": {
            "email": "birgitte.vestbjerg@leo-pharma.com", 
            "last_name": "Birgitte Vestbjerg", 
            "phone": "+45 44 94 58 88"
        }, 
        "overall_official": {
            "affiliation": "Gwinnett Clinical Research Center, Inc.", 
            "last_name": "Jonathan Weiss, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Part 1: Dose Limiting Toxicity up to and including Day 8", 
                "safety_issue": "Yes", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Part 2: Reduction in AK count", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 8"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100813"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Part 2: Complete clearance of AKs", 
                "safety_issue": "No", 
                "time_frame": "At Week 8"
            }, 
            {
                "description": "Partial clearance of AKs at Week 8, defined as at least 75% reduction from baseline in the number of clinically visible AKs", 
                "measure": "Part 2: Partial clearance of AKs", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }
        ], 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}